Emergent BioSolutions (EBS) Other financing activities (2010 - 2024)

Emergent BioSolutions (EBS) recorded quarterly Other financing activities of $8.7 million in Q3 2024, down 35.07% quarter-over-quarter from $13.4 million in Q4 2018.

Emergent BioSolutions (EBS) Other financing activities (2010 - 2024) Analysis & Trends

Emergent BioSolutions' Other financing activities history runs 10 years deep, the most recent figure standing at $8.7 million for Q3 2024.

  • In Q3 2024, Other financing activities changed N/A year-over-year to $8.7 million; the TTM figure through Dec 2025 stood at $8.7 million (changed 0.0% YoY), while the FY2024 annual figure was $14.6 million, changed N/A from the prior year.
  • Other financing activities was $8.7 million for Q3 2024 at Emergent BioSolutions, down from $13.4 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $8.7 million in Q3 2024 to a low of $8.7 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn
10 Emergent BioSolutions 415.46 Mn 253.96 Mn 84.10 Mn

Historic Data

Download Data
DateValue
Sep 30, 2024 8.70 Mn
Sep 30, 2024 8.70 Mn
Dec 31, 2018 13.40 Mn
Dec 31, 2018 13.40 Mn
Sep 30, 2018 -14.15 Mn
Sep 30, 2018 -14.15 Mn
Jun 30, 2018 8.09 Mn
Jun 30, 2018 8.09 Mn
Mar 31, 2018 6.07 Mn
Mar 31, 2018 6.07 Mn
Dec 31, 2017 43,000.00
Dec 31, 2017 43,000.00
Sep 30, 2017 -1.04 Mn
Sep 30, 2017 -1.04 Mn
Dec 31, 2016 -225,000.00
Dec 31, 2016 -225,000.00
Sep 30, 2016 383,000.00
Sep 30, 2016 383,000.00
Jun 30, 2016 16.23 Mn
Jun 30, 2016 16.23 Mn